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The Severe acute respiratory syndrome coronavirus (SARS-
CoV) main protease (Mpro) cleaves two virion polyproteins
(pp1a and pp1ab); this essential process represents an
attractive target for the development of anti-SARS drugs.
The functional unit of Mpro is a homodimer and each subunit
contains a His41/Cys145 catalytic dyad. Large amounts of
biochemical and structural information are available on Mpro;
nevertheless, the mechanism by which monomeric Mpro is
converted into a dimer during maturation still remains poorly
understood. Previous studies have suggested that a C-terminal
residue, Arg298, interacts with Ser123 of the other monomer
in the dimer, and mutation of Arg298 results in a monomeric
structure with a collapsed substrate-binding pocket. Interest-
ingly, the R298A mutant of Mpro shows a reversible substrate-
induced dimerization that is essential for catalysis. Here, the
conformational change that occurs during substrate-induced
dimerization is delineated by X-ray crystallography. A dimer
with a mutual orientation of the monomers that differs from
that of the wild-type protease is present in the asymmetric
unit. The presence of a complete substrate-binding pocket and
oxyanion hole in both protomers suggests that they are both
catalytically active, while the two domain IIIs show minor
reorganization. This structural information offers valuable
insights into the molecular mechanism associated with
substrate-induced dimerization and has important implica-
tions with respect to the maturation of the enzyme.
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1. Introduction
Coronaviruses (CoVs) belong to the order Nidovirales, which
are enveloped positive-stranded RNA viruses with a large
genome of about 30 kb (Gorbalenya et al., 2006). They include
important pathogens of humans and other animals (Weiss &
Navas-Martin, 2005). In late 2002, a novel CoV causing severe
acute respiratory syndrome (SARS) with a 15% fatality rate
emerged and spread to three continents in six months (World
Health Organization; http://www.who.int/csr/sars/country/
2003_08_15/en/). In the following few years, the discovery of
two further species of human CoVs, NL-63 and HCoV-HKU1,
as well as SARS-CoV-like strains in bats, conﬁrmed the great
diversity of CoVs (van der Hoek et al., 2004; Lau et al., 2005;
Li et al., 2005; Woo et al., 2005). In September 2012, the World
Health Organization was informed of several cases of acute
respiratory syndrome with renal failure owing to infection
with a novel CoV in the Middle East. The possible global
health implications are still under critical evaluation. Never-
theless, this re-emphasizes the possibility of the future re-
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emergence of SARS or a related disease. Therefore, studies to
aid our understanding of these viruses and the development of
novel antiviral inhibitors are both urgent and necessary.
The coronavirus nonstructural polyproteins (pp1a and
pp1ab) are cleaved by two kinds of viral cysteine proteases: a
main protease (Mpro or 3CLpro; EC 3.4.22.69) and a papain-
like protease (EC 3.4.22.46; Snijder et al., 2003). This process is
considered to be a suitable antiviral target because cleavage
is required for viral maturation (Wu et al., 2006; Chou et al.,
2008; Zhu et al., 2011). Mpro cleaves the polyproteins at 11 sites
that contain the canonical L-Q-#-(A/S/N) sequence (Hegyi &
Ziebuhr, 2002). Catalysis by Mpro has been studied extensively
over the years using both kinetic and mutagenesis approaches
(Anand et al., 2003; Chou et al., 2004; Hsu, Kuo et al., 2005; Lin
et al., 2008; Shi et al., 2008; Chen et al., 2008; Hu et al., 2009;
Cheng et al., 2010). Structural information is also available on
Mpro from SARS CoV and many other CoVs (Anand et al.,
2002; Yang et al., 2003; Xue et al., 2008; Zhao et al., 2008). The
structure of the coronaviral Mpro consists of three domains and
the catalytic dyad His/Cys is located at the interface between
domains I and II. The ﬁrst two domains have an antiparallel
-barrel structure that forms a folding scaffold similar to other
viral chymotrypsin-like proteases (Anand et al., 2002, 2003).
Domain III is a ﬁve-helix fold that contributes to the dimer-
ization of Mpro (Anand et al., 2002, 2003). There is a very long
loop (residues 176–200) between domains II and III. Recent
studies have suggested that foldon unfolding of SARS-CoV
Mpro domain III alone is able to mediate the interconversion
between the monomer and a three-dimensional domain-
swapped dimer under physiological conditions (Kang et al.,
2012); nevertheless, how the two domain IIIs meet and remain
together until -helix swapping takes place is still unknown.
Mature Mpro is a stable homodimer in which the two
subunits are arranged perpendicularly to each other (Yang et
al., 2003). Mutation or deletion of the N-ﬁnger (the ﬁrst seven
residues) and the C-terminus (residues 298–306) can lead to a
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Figure 1
AEC pattern of the R298Amutant of SARS-CoVMpro. The amount of protein used was 15 ml (1 mg ml1) and the total volume of the cell was 330 ml. (a)
A typical trace of the absorbance at 250 nm of the R298A mutant during an experiment at a substrate concentration of 200 mM. The symbols represent
experimental data and the lines are the results ﬁtted to the Lamm equation using the SEDFIT program (Chou et al., 2011; Schuck, 2000). The best-ﬁt
distribution result is shown by dashed lines in (c). (b) The absorbance at 405 nm tracing the released product (pNA) after the ﬁrst hour of the same
experiment. The time interval between two successive spectra, from black to cyan, is 10 min. The inset plot shows the product at different times. The line
indicates the best-ﬁt result for the initial velocity calculation. (c) The continuous c(s) distributions of the Mpro R298A mutant from the best-ﬁt analysis of
the 250 nm results. The distributions in 10 mM phosphate buffer pH 7.6 are shown by solid lines, while those in the presence of peptide substrate at 40
and 200 mM are shown as dotted and dashed lines, respectively. The two straight dashed lines indicate the positions of the monomer (M) and dimer (D).
The residual bitmaps of the raw data and the best-ﬁt results are shown as insets. (d) Plot of the initial velocities (from 405 nm results) versus substrate
concentration. The line represents the best-ﬁt results according to the Michaelis–Menten equation.
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monomeric Mpro with little enzyme activity (Yang et al., 2003;
Chou et al., 2004; Hsu, Chang et al., 2005). Mpro containing
additional N- and C-terminal segments of the polyprotein
undergoes autoprocessing to yield the mature protease in vitro
(Hsu, Kuo et al., 2005). Inactive as a monomer, the binding of
the peptide substrate or of an N-terminally and/or C-teminally
elongated Mpro molecule is able to induce dimerization of
Mpro, allowing catalysis (Cheng et al., 2010; Chen et al., 2010;
Li et al., 2010). The effect of substrate-induced dimerization
is reversible and can be blocked by the mutation of a key
residue, Glu166, which is responsible for the binding to Ser1 of
the other protomer and is one of the residues recognizing Gln
P1 of the substrate (Anand et al., 2002; Yang et al., 2003; Cheng
et al., 2010). In crystal structures of monomeric mutants of
SARS-CoV Mpro, such as R298A or G11A, the oxyanion loop
(Ser139–Cys145) is converted to a short 310-helix; this leads to
complete collapse of the oxyanion hole, resulting in enzyme
inactivation (Shi et al., 2008; Hu et al., 2009).
Despite the availability of a large amount of biochemical
and structural information on Mpro, the mechanism by which
monomeric Mpro is converted to a dimer during the matura-
tion process is currently poorly understood. Here, we report
the crystal structure of the SARS-CoV Mpro R298A mutant
in the presence of peptide substrate. The structure reveals a
functional dimeric form but with a minor change in the rela-
tive orientation of the two domain IIIs. Detailed exploration
of this structure provides a better and more detailed under-
standing of the mechanisms that control the dimerization of
coronaviral Mpro.
2. Materials and methods
2.1. Protein expression and purification
The R298A mutant of SARS-CoV Mpro inserted into the
pET-28a(+) vector (Cheng et al., 2010) was expressed in
Escherichia coli BL21 (DE3) cells. Cultures were grown in LB
medium at 310 K for 4 h and were then induced with 0.4 mM
isopropyl -d-1-thiogalactopyranoside; this was followed by
overnight incubation at 293 K. After centrifugation at 6000g
at 277 K for 10 min, the cell pellets were resuspended in lysis
buffer (20 mM Tris pH 8.5, 250 mM NaCl, 5% glycerol, 0.2%
Triton X-100, 2 mM -mercaptoethanol) and lysed by soni-
cation. The crude extract was then centrifuged at 12 000g at
277 K for 25 min to remove the insoluble pellet. The super-
natant was incubated with 1 ml Ni–NTA beads (Qiagen,
Hilden, Germany) at 277 K for 1 h and loaded into an empty
column. After ﬂowthrough and washing with washing buffer
(20 mM Tris pH 8.5, 250 mM NaCl, 8 mM imidazole, 2 mM
-mercaptoethanol), the protein was eluted with elution
buffer (20 mM Tris pH 8.5, 30 mM NaCl, 150 mM imidazole,
2 mM -mercaptoethanol). The resulting protein fraction was
then loaded onto an S-300 gel-ﬁltration column (GE Health-
care) equilibrated with running buffer (20 mM Tris pH 8.5,
100 mM NaCl, 2 mM dithiothreitol). The purity of the
collected fractions was analyzed by SDS–PAGE. Fractions
containing the Mpro protein were pooled and concentrated to
30 mg ml1 using an Amicon Ultra-4 30 kDa centrifugal ﬁlter
(Millipore). The typical yield of protein was 5–10 mg per litre
of cell culture.
2.2. Active enzyme centrifugation
Active enzyme centrifugation (AEC) can be used to
observe quaternary-structural changes and catalytic activity
simultaneously (Chou et al., 2011). The analytical ultra-
centrifugation experiments were performed with an XL-A
analytical ultracentrifuge (Beckman, Fullerton, California,
USA) using an An-50 Ti rotor (Cheng et al., 2010). A
commercially available double-sector Vinogard-type band-
forming centrepiece (Beckman, Fullerton, California, USA)
was used for AEC (Chou et al., 2011; Chou & Tong, 2011).
Brieﬂy, 15 ml of the R298A mutant of Mpro (1 mg ml1) was
added to the small well above the sample sector. After the cell
had been assembled, 330 ml peptide substrate (TSAVLQ-pNA
from GL Biochem, Shanghai, People’s Republic of China)
dissolved in D2O at 0, 40 or 200 mM was loaded into the bulk-
sample sector space. Centrifugation was then carried out at
42 000 rev min1. Absorbance at 250 nm was chosen to allow
detection of the protein band, while absorbance at 405 nm was
used to monitor the catalytic release of the product, pNA. The
spectrum was recorded continuously using a time interval of
600 s per scan and a step size of 0.003 cm. A typical trace of
the 250 nm spectral results is shown in Fig. 1(a). The data set
was then ﬁtted to a continuous c(s) distribution model using
the SEDFIT program (Schuck, 2000; Brown & Schuck, 2006).
The signals at 405 nm were used to calculate the initial
velocities and were then ﬁtted to the Michaelis–Menten
equation, from which the kinetic parameters Km and kcat were
determined (Chou et al., 2011).
2.3. Protein crystallization
Crystals of the R298A mutant were obtained at 295 K by
the sitting-drop vapour-diffusion method. The protein solution
was set up at 15 mg ml1 and included 1 mM TSAVLQ-pNA.
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Table 1
Summary of crystallographic information for Mpro R298A (pH 8.0).
Values in parentheses are for the highest resolution shell.
Space group P1
Unit-cell parameters (A˚, ) a = 55.0, b = 59.4, c = 59.8,
 = 71.3,  = 73.4,  = 72.3
Resolution (A˚) 30–2.09 (2.20–2.09)
Rmerge† (%) 3.5 (22.0)
hI/(I)i 21.5 (3.2)
Completeness (%) 94.7 (82.6)
No. of reﬂections 35837 (4672)
Multiplicity 2.2 (2.0)
R factor‡ (%) 19.0
Free R factor§ (%) 24.1
R.m.s.d., bond lengths (A˚) 0.009









i IiðhklÞ, where Ii(hkl) is the integrated
intensity of a given reﬂection and hI(hkl)i is the mean intensity of multiple corresponding








hkl jFobsj, where Fobs and
Fcalc are the observed and calculated structure factors, respectively. § The free R factor
is the R factor calculated using a random 5% of data that were excluded from the
reﬁnement.
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The reservoir solution consisted of 0.1M Tris pH 8.0,
30%(w/v) PEG 300, 5%(w/v) PEG 1000. Large but poorly
diffracting crystals appeared in 3 d and were used for micro-
seeding. Single crystals of cubic shape and with dimensions of
0.2–0.3 mm were obtained in less than a week. All crystals
were cryoprotected in reservoir solution with 1 mM TSAVLQ-
pNA and were then ﬂash-cooled in liquid nitrogen. Crystal
soaking in 2 mM TSAVLQ-pNA failed to improve the
electron density of the substrate. Soaking at higher peptide
concentrations was impossible owing to low solubility.
2.4. Data collection, structure
determination and refinement
X-ray diffraction data were collected
at 100 K on SPXF beamline 13B1 at
the National Synchrotron Radiation
Research Center (Taiwan) using an
ADSC Quantum-315r CCD (X-ray
wavelength 0.976 A˚). The diffraction
images were processed and scaled using
the HKL-2000 package (Otwinowski &
Minor, 1997). The crystal belonged to
space group P1, with unit-cell para-
meters a = 55.0, b = 59.4, c = 59.8 A˚,
 = 71.3,  = 73.4,  = 72.3. There are
two Mpro molecules in the asymmetric
unit. The structure was solved by the
molecular-replacement method with the
program Phaser (McCoy et al., 2007)
using the structure of wild-type Mpro
(PDB entry 1uk4) as the search model
(Yang et al., 2003). Manual rebuilding of
the structure model was performed with
Coot (Emsley & Cowtan, 2004). Struc-
ture reﬁnement was carried out using
the program REFMAC (Murshudov et
al., 2011). Data-processing and reﬁne-
ment statistics are summarized in
Table 1. The crystal structure has been
deposited in the Protein Data Bank
(PDB entry 4hi3).
3. Results and discussion
3.1. Substrate-induced dimerization of
SARS-CoV Mpro
To explore the inﬂuence of substrate
binding on the dimerization of Mpro, we
performed AEC experiments on the
R298A mutant of Mpro with or without
the peptide substrate. Figs. 1(a) and 1(b)
show typical absorbance traces at 250
and 405 nm of the R298A mutant
during the experiment at a substrate
concentration of 200 mM. After ﬁtting
the 250 nm signals to the continuous
size-distribution model, it was obvious that the R298A mutant
was monomeric (2.1 S) in the absence of substrate (Fig. 1c,
solid lines), whereas it was dimeric (2.8 S) at a substrate
concentration of 200 mM (Fig. 1c, dashed lines). Somewhat
surprisingly, at a substrate concentration of 40 mM the major
species (2.3 S) of the R298A mutant was located between the
monomer and the dimer (Fig. 1c, dotted lines). According to
previous studies, these results suggested that the R298A
mutant is a rapid self-association protein, similar to wild-type
Mpro (Cheng et al., 2010). These observations using AEC
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Figure 2
Dimeric structure of the R298A mutant of SARS-CoVMpro. (a) The overall structure of the dimeric
Mpro R298A mutant. The two protomers are coloured cyan and green, respectively. (b) Crystal
packing of the R298A mutant. Two molecules form a biological dimer in the unit cell. (c) Final
2Fo  Fc electron density contoured at 1.0 for residues 297–299 of the R298A mutant. The Arg298
residue in wild-type Mpro is also shown (grey). (d) Schematic drawing in stereoview showing the
detailed interactions at the active site of the R298A mutant. The residual electron density around
the active site is contoured at 2.5 (green mesh) and the C atoms of the modelled P3–P1 (Val-Leu-
Gln) residues are coloured orange. Hydrogen-bonding interactions are indicated by red dashed
lines. All structure ﬁgures were produced with PyMOL (http://www.pymol.org).
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conﬁrmed the substrate-induced dimerization of the R298A
mutant. Moreover, after calculating the initial velocities from
signals at 405 nm and then ﬁtting them to the Michaelis–
Menten equation (inset in Figs. 1b and 1d), an apparent Km of
380 mM and an apparent kcat of 0.012 s
1 were calculated.
These values are very close to those for wild-type Mpro from
AEC analysis (Chou et al., 2011). This conﬁrmed that the
dimeric R298A protein is functionally the same as that of wild-
type Mpro. However, based on the crystal structure of the
monomeric R298A mutant (Shi et al., 2008), the transition
from monomer to dimer should be impossible because of the
dramatic rotation of domain III and the formation of a short
310-helix from an active-site loop; these changes result in the
catalytic machinery being frozen in a collapsed state.
Furthermore, recent studies suggested that the R298E mutant
maintained N-terminal autocleavage activity comparable to
that of wild-type Mpro, although it did cause complete dimer
dissociation and disruption of trans-cleavage activity (Chen et
al., 2010). This indicated that N-terminal autocleavage of Mpro
is not dependent on a ‘mature’ dimeric protease, but on an
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Figure 3
Comparisons with the monomeric structure of the R298A mutant of Mpro. (a) Overlay of the current structure of the R298A dimer (in cyan and green)
with that of the R298A monomer (grey; Shi et al., 2008). The orientation of domain III shows a 33 change compared with that in the monomer. The red
lines represent the positions of residues 193–200 in the two structures. The region in the box is enlarged in (b). (b) Detailed interactions at the dimer
interface of the R298A mutant. The red dashed lines indicate hydrogen bonds associated with the dimer, while black dashed lines indicate hydrogen
bonds in the monomer. (c) Substrate-binding cavities mapped onto the current structure. Both protomers show a large and deep cavity (magenta surface
representation) near the catalytic dyad, which is essentially the same as that in wild-type Mpro at pH 7.6, although wild-type Mpro at pH 6.0 shows one
active protomer and one inactive protomer (Yang et al., 2003). The cavity was calculated using DS Modeling 1.7 (Accelrys) and was drawn using
Discovery Studio Visualizer 2.5 (Accelrys).
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‘intermediate’ or ‘loose’ dimer (Chen et al., 2010). On the
other hand, we have expressed and puriﬁed an R298A mutant
with an N-terminal extension similar to that of the R298E
mutant (Chen et al., 2010). However, the mutant lost its trans-
cleavage activity (less than 0.8%) and failed to form a dimer
even in the presence of peptide substrates (Supplementary
Fig. 11). Efforts to crystallize the N-terminally extended
R298A mutant were also unsuccessful. To delineate the
mechanism for the conversion of Mpro from an inactive
monomer to a functional dimer, we next determined the
crystal structure of the dimeric R298A mutant at a resolution
of 2.09 A˚ (Table 1). It is important to note that we used an
R298Amutant with an authentic N-terminus and a C-terminus
with eight extra residues (LEH6) for convenience in puriﬁca-
tion. According to previous studies (Chen et al., 2010), in the
presence of peptide substrates the structure should be more
like a mature dimer with trans-cleavage activity, not a pre-
mature dimer with an N-terminal extension.
3.2. Overall structure of the R298A mutant of SARS-CoV
Mpro in the presence of peptide substrate
The original goal of our experiment was to determine the
binding modes of peptide substrates to the R298A mutant. We
therefore included high concentrations of peptide substrate
(1 mM; threefold higher than the Km) in the cocrystallization
conditions. The reﬁned atomic model agreed well with the
crystallographic data and the expected bond angles and bond
lengths (Table 1). About 91% of the residues are in the most
favoured region of the Ramachandran plot; none are in the
disallowed region.
Consistent with our expectations and the AEC results, two
essentially identical monomers of the R298A mutant exist in
the asymmetric unit, with an r.m.s.d. of 1.1 A˚ between their C
atoms (Figs. 2a and 2b). There is a minor change in orientation
between the two copies of domain III and therefore the
r.m.s.d. value decreases to 0.28 A˚when domain III is excluded.
The overall structure of the dimeric R298A mutant is similar
to other structures of SARS-CoV Mpro reported previously.
For example, the r.m.s.d. between equivalent C atoms of this
dimeric structure and the structure of wild-type Mpro at pH 8.0
is 0.59 A˚ (Yang et al., 2003). The r.m.s.d. is 0.41 A˚ when the
structure is compared with that of wild-type Mpro in complex
with a peptide aldehyde inhibitor (Zhu et al., 2011). However,
the position of domain III is different when these structures
are compared (see below) and has been excluded from the
comparisons.
Our crystallographic analysis of the R298A mutant shows
that there is no evidence for any electron density beyond the
C atom of this side chain (Fig. 2c). This is a conﬁrmation that
our protein carries the R298A mutation and that only mutant
protein was crystallized in our experiments. Unfortunately, we
cannot observe the complete electron density of the peptide
substrate, even though there is some residual electron density
near the His41/Cys145 catalytic dyad of subunitA (green mesh
in Fig. 2d). To evaluate the possible substrate-binding mode in
this structure, we generated a model with the P3–P1 substrate
residues (Val-Leu-Gln) based on the structure of the C145A
mutant (Hsu, Kuo et al., 2005). In the model, the side chains of
P1 Gln and P2 Leu are able to ﬁll the residual electron density
and an O atom of the carboxyl group of P1 Gln is located in
the oxyanion hole (Fig. 2d). In contrast, in subunit B there is
no residual electron density at the same position, suggesting
that the statuses of the two active sites in the dimer may not be
identical, although the amide N atoms of Gly143 and Cys145
in each subunit are oriented into the oxyanion hole. In addi-
tion, most of the residues in the active site, including Phe140,
His163, Glu166, His172 and the catalytic dyad His41/Cys145,
are in the same positions as those of wild-type Mpro (Yang et
al., 2003). This seems to conﬁrm that the catalytic machinery
of the R298A dimer is functional.
3.3. Comparison with the monomeric structure of the R298A
mutant
The mutual arrangement of the domains of the R298A
mutant is changed dramatically and therefore we compared
our dimer structure with that of the monomer (PDB entry
2qcy; Shi et al., 2008) based on superposition of domains I and
II. As shown in Fig. 3(a), the most obvious conformational
change is a 33 rotation of domain III. This rotation allows
steric hindrance between the two copies of domain III during
dimerization to be avoided. The variability of the mutual
domain arrangement suggests that conversion from the
monomeric form to the dimeric form is feasible. Nevertheless,
the dimerization of some other monomeric mutations, such as
G11A and S139A, still needs to be conﬁrmed, although they
show a similar overall structure to the R298A monomer (Chen
et al., 2008; Hu et al., 2009).
The structural comparison also shows that in the present
structure the short 310-helix of residues Ser139-Phe140-
Leu141 is disrupted and adopts a loop conformation similar to
that of the wild type (Fig. 3b; see below). The unfolding of this
helix enables the insertion of the N-ﬁnger of the other subunit,
which is further stabilized by the interaction of Glu166 with
Ser10 (primed residue numbers indicate subunit B; Fig. 3b).
Most importantly, the key stacking interaction between the
rings of Phe140 and His163, which is important to prevent
His163 from being protonated (Yang et al., 2003), are main-
tained (Fig. 2d). This ensures that His163 can efﬁciently
interact with the side chain of P1 Gln. In contrast to the
collapsed substrate-binding site in the R298A monomer (Shi
et al., 2008), there is a large and complete substrate-binding
pocket in each subunit (Fig. 3c). This further suggests that
both subunits of the R298A dimer are catalytically active.
In addition, at the dimer interface of the present structure,
ion pairs and hydrogen bonds, such as Arg40–Glu290 and
Ser139–Gln2990, can also be seen, which is a similar situation
to that of the wild-type structure (Fig. 3b; see below). All of
these observations conﬁrm that the dimerization of R298A is
very similar to that of wild-type Mpro, with only minor differ-
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1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: DW5035). Services for accessing this material are described at the
back of the journal.
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ences. Owing to the lack of a monomeric wild-type Mpro
structure, the monomeric and dimeric R298A structures
provide valuable insights into the dimerization process of the
enzyme, which undergoes a dramatic mutual arrangement of
the domains (Hsu, Kuo et al., 2005; Chen et al., 2008, 2010;
Cheng et al., 2010; Li et al., 2010).
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Figure 4
Comparisons with the structure of wild-type Mpro. (a) An overlay of the current structure of the R298A dimer (cyan and green) with that of wild-type
Mpro in complex with peptidyl aldehyde inhibitor (magenta; PDB entry 3snd; Zhu et al., 2011). The red arrows show the orientation change affecting the
two domain IIIs. The region in the box is enlarged in (b). (b) The hydrogen-bonding interaction between the two domain IIIs. The red dashed line
indicates the hydrogen bond between Ser284 and Thr2850 in the R298A mutant, while the black dashed lines show hydrogen bonds between the two
Thr285 residues and the associated water (red sphere) in wild-type Mpro. (c) and (d) show the detailed interactions of the two protomers near the active
sites of subunit A (cyan) and subunit B (green), respectively. The red dashed lines indicate hydrogen bonds and ion pairs for the R298A mutant, while
wild-type Mpro (magenta) shows the same interactions (PDB entry 3snd; Zhu et al., 2011). Overlay of the P2–P1 residues in the two structures (orange in
R298A structures and grey in wild-type Mpro, respectively) conﬁrmed that one O atom of the carboxyl group of P1 Gln was located in the oxyanion hole.
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3.4. Reorganization of the dimer in the R298A mutant
The R298A mutant shows an apparent change in the rela-
tive orientation of domain III. When we compared our
structure with two wild-type structures (Yang et al., 2003; Zhu
et al., 2011), namely the free enzyme at pH 8.0 (PDB entry
1uk2) and the peptide aldehyde inhibitor complex (PDB entry
3snd), a relative shift of 5–24 could be observed for the two
copies of domain III in the dimer compared with the free
enzyme, while there was a shift of 6–17 compared with the
inhibitor complex (Fig. 4a). Interestingly, we found that there
is a hydrogen-bonding interaction between residues Ser284
and Thr2850 in the I–J loop, while there is a water molecule
between the two Thr285 residues in the structure of wild-type
Mpro (Fig. 4b). The direct contact between the two I–J loops
leads to a shift of the I and J helices, further causing the
change in the orientation of the whole domain III. This
observation also suggests that the two copies of the folded
domain III are able to bind to each other by this interaction at
the initial stage and to wait until the swapping of the -helix to
form a three-dimensional domain-swapped dimer or a more
stable and super-active octameric Mpro (Zhang et al., 2010;
Kang et al., 2012).
Furthermore, in the present structure each domain III is
even closer to domains I and II of the other subunit, although
subunitA shows a larger change in orientation than subunit B.
At the dimer interface of the R298A mutant, in addition to
two intermolecular Arg4–Glu290 ion pairs (Arg4–Glu2900 and
Arg40–Glu290), there are two Ser139  Gln299 hydrogen
bonds (Ser139  Gln2990 and Ser1390  Gln299) and two
Ser1–Glu166 ion pairs (Ser1–Glu1660 and Ser10–Glu166); this
contrasts with some of the structures of wild-type Mpro (PDB
entries 1uk2 and 1uk4), which only show one pair of each. A
similar assembly can also be observed in the structures of
authentic wild-type Mpro (PDB entry 2h2z) and its complex
with a peptide aldehyde inhibitor (PDB entry 3snd), although
in these two structures the Arg298 residues do not interact
with Ser123 of the other subunit (Figs. 4c and 4d; Xue et al.,
2007; Zhu et al., 2011). This suggests that Mpro may not require
all of the possible intermolecular interactions for dimerization,
especially in the presence of substrates or peptidyl inhibitors.
Moreover, previous studies have suggested that Glu166 plays
a pivotal role in connecting the substrate-binding site to the
dimer interface (Yang et al., 2003; Chen et al., 2008; Cheng et
al., 2010). In our structure, the interactions between the main-
chain amide of Ser1 with the carboxyl group of the Glu166
side chain of the other subunit provide direct evidence to
explain why the mutation at Glu166 blocks substrate-induced
dimerization of Mpro (Cheng et al., 2010). Remarkably,
mutation of Arg298, which should be detrimental to dimer-
ization, may be compensated by these interactions, while most
of the other residues in the active site show only small changes.
4. Conclusion
Our studies show that SARS-CoV Mpro, the dimerization of
which is important for its catalytic activity, is able to tolerate
large orientation changes, especially involving domain III.
Mutation of Arg298, when introduced at the dimer interface,
disturbs the dimerization; nevertheless, in the presence of
peptide substrate the dimerization is able to be induced or
rescued by intermolecular hydrogen-bond (Ser139  Gln299)
and ion-pair (Ser1–Glu166) interactions. Based on the exis-
tence of a complete substrate-binding pocket and a complete
oxyanion hole, we suggested that the dimer is still catalytically
active, even though there are conformational rearrangements
of the two copies of domain III in the dimer. AEC experi-
ments conﬁrmed that the kinetic parameters of the R298A
mutant are similar to those of wild-type Mpro. The present
studies provide valuable insights into the mechanisms that
control the monomer–dimer switch during the maturation
process of Mpro.
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